An interventional study of AKL-T01 in Attention Deficit Hyperactivity Disorder, sponsored by Akili Interactive Labs, Inc.. Completed at 14 sites in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-08-14.
Sponsored by Akili Interactive Labs, Inc. · Not applicable, Interventional, and Treatment
The purpose of this study is to evaluate the effects of videogame-like digital therapy on attentional functioning and symptoms in adolescents ages 13-17 diagnosed with ADHD
This study is a multi-center, unblinded/non-controlled study to evaluate objective attention functioning and ADHD symptoms and impairments in adolescents aged 13 to 17 years old, with a diagnosis of ADHD (combined or inattentive subtype), stably on or off ADHD medication, after 4-weeks of AKL-T01 treatment.
Up to 165 total participants from up to 20 sites will be enrolled.
During the Screening/baseline, participants will undergo screening to evaluate eligibility for the study. Eligible participants will continue onto baseline procedures in the same visit.
Treatment phase (Day 2-27) will involve using the digital therapy at home for each participant. Compliance with treatment/use requirements will be monitored remotely during this phase.
An In-Clinic assessment will be completed on Day 28 to assess key outcomes.
1,514 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 255 are open to participants now.
This study's enrollment of 165 is above the median of 72 across 1,207 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Browse Attention Deficit Disorder with Hyperactivity studies →Akili Interactive Labs, Inc. is the lead sponsor of 12 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Digital Treatment
Device: AKL-T01
AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor "driving" task.
Primary objective of this study is to evaluate the efficacy of AKL-T01 as determined by the change in a digitally assessed measure after 4 weeks of treatment
Test of Variables of Attention (TOVA)-Attention Comparison Score (ACS) of sustained and selective attention. Measures at Day 1 and Exit/Post-Treatment Visit Day 28 TOVA ACS is a comparison of a subject's scores based on selected measures that persons with an independent diagnosis of ADHD frequently demonstrated. ACS is calculated using the following formula: ACS = Response Time Z score (Half 1) + d' Z score (Half 2) + Variability Z score (Total) + 1.80 where Response Time is the average time it takes to respond correctly to a target, d' score is a response discriminability score reflecting the ratio of hits to "false alarms", and Variability is a measure of consistency of speed of responding based on the standard deviation of the mean correct response times. ACS tells how similar the score is to the ADHD profile. A score of less than 0 indicates that the subject had similar performance to a normative ADHD population. A lower score indicates a more severe ADHD profile.
Time frame: After 4 weeks of treatment with AKL-T01
Secondary objective of this study is to evaluate the change in ADHD symptoms
Change in the Attention Deficit Hyperactive Disorder (ADHD) Rating Scale-5 inattention sub-scale and total scale scores. Measures taken at Baseline Visit (Day 1) and Exit/Post-Treatment Visit (Day 28). ADHD Rating Scale-5 is a clinician-administered questionnaire completed by the child's parent. The scale consists of two symptom subscales: Inattention and Hyperactivity-Impulsivity. The Inattention subscale raw score is computed by summing the item scores for 9 items. The total score is obtained by adding the Inattention and Hyperactivity-Impulsivity subscale raw scores. Each item is rated on a 4-point scale; Never or Rarely (0), Sometimes (1), Often (2), Very Often (3) with total scores ranging from 0-54. A higher score indicates more severe ADHD symptoms and behaviors.
Time frame: After 4 weeks of treatment with AKL-T01
To evaluate the change in patient and caregiver perceived cognitive deficits
The change will be determined in selected items from the PROMIS® Parent Proxy Item Bank v1.1 - Cognitive Function and the PROMIS® Pediatric Item Bank v1.0-Cognitive Function
Time frame: After 4 weeks of treatment with AKL-T01
To evaluate changes in functional impairment
The change will be determined in ADHD-Rating Scale 5 Home Version relationship with significant others, peer relationships, academic functioning, behavioral functioning, homework functioning and self-esteem domains. ADHD Rating Scale-5 is a clinician-administered questionnaire completed by the child's parent. The scale asses six domains of impairment that are common among children with ADHD with one question item per domain. The scale is administered twice, once after each set of symptom subscale items (Inattention and Hyperactivity-Impulsivity). Each item is rated on a 4-point scale; No Problem (0), Minor Problem (1), Moderate Problem (2), Severe Problem (3). A higher score indicates more severe impairment due to ADHD symptoms and behaviors.
Time frame: After 4 weeks of treatment with AKL-T01
To evaluate changes in TOVA metrics other than ACS - Ex-Gaussian Tau Total
To evaluate changes in the following additional Test of Variables of Attention (TOVA) metrics other than Attention Comparison Score (ACS) - Ex-Gaussian Tau. TOVA is a comparison of a subject's scores based on selected measures that persons with an independent diagnosis of ADHD frequently demonstrated. TOVA metric evaluated for change is: * Ex-Gaussian Tau: The exponential decay (or "right hand tail") of the correct response times, modeled using the Ex-Gaussian distribution. Total refers to entire test (both H1 and H2). H1 refers to the first half of the test where target stimulus is infrequent (1 target to 3.5 non-targets), and H2 represents the second half where target stimulus is frequent (3.5 targets to 1 non-target). Measures at Day 1 and Exit/Post-Treatment Visit Day 28.
Time frame: After 4 weeks of treatment with AKL-T01
To evaluate changes in TOVA metrics other than ACS - Commission Errors Standard Score H2
To evaluate changes in the following additional Test of Variables of Attention (TOVA) metrics other than Attention Comparison Score (ACS) - Commission Errors Standard. TOVA is a comparison of a subject's scores based on selected measures that persons with an independent diagnosis of ADHD frequently demonstrated. TOVA metric evaluated for change is: -- Commission Errors Standard Score H2: Commission errors are the number of times the patient clicked the microswitch at the incorrect time. H2 represents the second half where target stimulus is frequent (3.5 targets to 1 non-target). Measures at Day 1 and Exit/Post-Treatment Visit Day 28.
Time frame: After 4 weeks of treatment with AKL-T01
To evaluate changes in TOVA metrics other than ACS - Response Time Variability Standard Score Total
To evaluate changes in the following additional Test of Variables of Attention (TOVA) metrics other than Attention Comparison Score (ACS) - Response Time Variability Standard Score Total. TOVA is a comparison of a subject's scores based on selected measures that persons with an independent diagnosis of ADHD frequently demonstrated. TOVA metric evaluated for change is: - - Response Time Variability Standard Score Total: The standard score for the first standard deviation of the correct response times. Total refers to entire test (both H1 and H2). H1 refers to the first half of the test where target stimulus is infrequent (1 target to 3.5 non-targets), and H2 represents the second half where target stimulus is frequent (3.5 targets to 1 non-target). Measures at Day 1 and Exit/Post-Treatment Visit Day 28.
Time frame: After 4 weeks of treatment with AKL-T01
To evaluate changes in TOVA metrics other than ACS - Response Time Mean Standard Score H1
To evaluate changes in the following additional Test of Variables of Attention (TOVA) metrics other than Attention Comparison Score (ACS) - Response Time Mean Standard Score H1. TOVA is a comparison of a subject's scores based on selected measures that persons with an independent diagnosis of ADHD frequently demonstrated. TOVA metric evaluated for change is: * - Response Time Mean Standard Score H1:The standard score for the mean response time of the correct responses. H1 refers to the first half of the test where target stimulus is infrequent (1 target to 3.5 non-targets). Measures at Day 1 and Exit/Post-Treatment Visit Day 28.
Time frame: After 4 weeks of treatment with AKL-T01
To evaluate changes in TOVA metrics other than ACS - D-Prime Standard Score H2
To evaluate changes in the following additional Test of Variables of Attention (TOVA) metrics other than Attention Comparison Score (ACS) - D-Prime Standard Score H2. TOVA is a comparison of a subject's scores based on selected measures that persons with an independent diagnosis of ADHD frequently demonstrated. TOVA metric evaluated for change is: -- D-Prime Standard Score H2: D-Prime score is a response discriminability score reflecting the ratio of hits to false alarms. The measure is derived from Signal Detection Theory and has been shown to help distinguish non-impaired individuals from those diagnosed with attention disorders. The score reflects the accuracy of target (signal) and nontarget (noise) discrimination and can be interpreted as a measure of perceptual sensitivity. H2 represents the second half where target stimulus is frequent (3.5 targets to 1 non-target). Measures at Day 1 and Exit/Post-Treatment Visit Day 28.
Time frame: After 4 weeks of treatment with AKL-T01
To evaluate changes in TOVA metrics other than ACS - Omission Errors Standard Score H2
To evaluate changes in the following additional Test of Variables of Attention (TOVA) metrics other than Attention Comparison Score (ACS) - Omission Errors Standard Score H2. TOVA is a comparison of a subject's scores based on selected measures that persons with an independent diagnosis of ADHD frequently demonstrated. TOVA metric evaluated for change is: - - Omission Errors Standard Score H2: Omission Errors are the number of times the patient failed to click the microswitch when the target was presented. H2 represents the second half where target stimulus is frequent (3.5 targets to 1 non-target). Measures at Day 1 and Exit/Post-Treatment Visit Day 28.
Time frame: After 4 weeks of treatment with AKL-T01
To evaluate response rates for TOVA-ACS
The change will be determined in responder analyses for Test of Variables of Attention, Attention Comparison Score (TOVA-ACS). TOVA-ACS is a comparison of a subject's scores based on selected measures that persons with an independent diagnosis of ADHD frequently demonstrated. ACS is calculated using a standardized formula. Responder rates will be 1.0-point improvement and TOVA-ACS greater then or equal to 1.0 at exit visit. Measures at Day 1 and Exit/Post-Treatment Visit Day 28.
Time frame: After 4 weeks of treatment with AKL-T01
To evaluate response rates for ADHD Rating Scale-5
The change will be determined in responder analyses for ADHD Rating Scale 5. ADHD Rating Scale-5 is a clinician-administered questionnaire completed by the child's parent. The scale asses six domains of impairment that are common among children with ADHD with one question item per domain. Greater than or equal to 30% improvement in ADHD RS-5 total score from baseline after 4 weeks of AKL-T01 treatment. Measures at Day 1 and Exit/Post-Treatment Visit Day 28.
Time frame: After 4 weeks of treatment with AKL-T01
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Attention Deficit Disorder with Hyperactivity→
Akili Interactive Labs, Inc.